We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
News

BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project

BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
News

BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BIOCRATES life sciences will play a pivotal role in one of the latest framework six EU projects called COBRED. COBRED’s participants will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.

Each partner brings specific strengths to the project, creating a strong R&D collaboration. Biocrates’ strengths lie in targeted metabolomics.

Brad Morie, Chief Business Development Officer at Biocrates, said "This project comes at a perfect time for us. We have officially launched our proprietary targeted metabolomics services platform, TargetIDQ™."

Mr. Morie continued, "TargetIDQ™ has proven effective in our collaborations with pharmaceutical companies and helped us discover metabolic biomarkers. We plan to leverage TargetIDQ™ to identify and quantify over 1000 metabolites in the COBRED study, ultimately yielding novel cancer biomarkers."

Eight partners from France, Hungary, Estonia, and Austria will collaborate to discover biomarkers which assess the risk of cancer recurrences after initial tumor removal. Klaus Weinberger, Biocrates’ CSO, explained, “COBRED provides an excellent platform for translational research because of the close interaction between the best clinical centers and analytical/technology partners. The overarching goal is to develop better means of cancer detection than current expensive and invasive diagnostic techniques.”

Armin Graber, Biocrates’ CEO, stated, “Our vision is to apply these novel treatments to a larger, population-based screening program. A successful outcome will ease the burden on social medicine programs, because early detection has proven to increase the efficacy of treatment and lower costs for all cancers.”

Advertisement